In this free webinar, gain insights into an intracellular delivery platform to internalize biotherapeutics to specific target cells. Attendees will learn about molecular guidance systems (MGSs) that can be identified for virtually any cell type. The featured speaker will discuss a novel immunotherapy to use in combination with checkpoint inhibitors, and more.
TORONTO, Jan. 24, 2024 /PRNewswire-PRWeb/ -- Explore this webinar on a peptide ligand, called molecular guidance system 5 (MGS5), targeting N-glycolylneuraminic acid (Neu5Gc)-Sialyl LewisA in cancer, enhancing early detection and advancing liposome-based immunotherapy for pancreatic cancer.
Glycosylation is a post-translation modification that is commonly altered in cancer, playing fundamental roles in cell signaling, cell migration and invasion, immune modulation and metastasis. Neu5Ac-Sialyl LewisA (CA19-9), part of the Lewis blood antigen family, is a well-studied blood biomarker that is Food and Drug Administration (FDA) approved for the detection of pancreatic cancer. However, its counterpart, N-glycolylneuraminic acid (Neu5Gc)-Sialyl LewisA, is under-studied in human malignancies due to the inactivation of the cytidine monophospho-N-acetylneuraminic acid hydroxylase (CMAH) gene and the absence of Neu5Gc-Sialyl LewisA specific targeting molecules.
This webinar will discuss a liposome-based immunotherapy ("Targeted Antigen Loaded Liposomes" TALL) that consists of three modular components:
1) pegylated stealth phospholipid layer;
2) an encapsulated synthetic immunogenic MHC class I restricted peptide derived from the measles virus; and
3) MGS5 on the external surface for tumor targeting.
MGS5 binds to the surface of the cancer cells via Neu5Gc-Sialyl LewisA and is subsequently internalized allowing for the internalization of the liposome and the release of the encapsulated antigenic peptide. This in turn elicits a robust immune response. TALL, in combination with an anti-programmed cell death protein 1 (PD-1) inhibitor, results in a 10-fold reduction in tumor burden in mice bearing orthotopic breast and pancreatic tumors, compared to using anti-PD-1 alone.
Join this webinar to learn not only how MGS5 is a novel peptide for the detection of Neu5Gc- Sialyl LewisA, but how it can also serve as a therapeutically relevant cancer targeting agent allowing for the delivery of therapeutics.
Join Shelby Knoche PhD, SRI International, for the live webinar on Wednesday, January 31, 2024, at 2pm EST (11am PST).
For more information, or to register for this event, visit Immunotherapy for Pancreatic Cancer: Peptidic Targeting of a Tumor-Specific Glycan.
ABOUT XTALKS
Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars and digital content to the global life science, food, healthcare and medical device communities. Every year, thousands of industry practitioners (from pharmaceutical, biotechnology, food, healthcare and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps professionals stay current with industry developments, regulations and jobs. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.
To learn more about Xtalks visit http://xtalks.com
For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/
Media Contact
Vera Kovacevic, www.xtalks.com, +1 (416) 977-6555 x371, [email protected]
SOURCE Xtalks
Share this article